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Abstract PHF-tau, which is pbosphorylated at 10 SerfFhr-Pro 
and 11 non-SerfFhr-Pro sites, is unable to promote microtubule 
assembly. Phosphorylation of the non-Ser/Thr-Pro site, Ser-262, 
is reported to be primarily responsible for this. The identifies of 
kinnse(s) responsible for Ser-262 phnspborylation are still to be 
clarified. In this study we have used the monoclonal antibody 
12E8, which recognizes P-Set-262 and P-Set-356 on tau, to 
survey different kinases for their abilities to phospborylate Ser- 
262 on human tau 3L (tau410). In decreasing order of 
effectiveness we found that Ser-262 and Ser-356 phosphorylation 
can be catalyzed by CaM kinase II >> C-kinase >> GSK-3-  = A- 
kinase>>CK-l. CaM kinase II and C-kinase were shown to 
phosphorylate both Ser-262 and Ser-356. The binding of tau to 
taxol-stabilized microtubules was decreased by 35 and 42% after 
phosphorylation by CaM kinase II and C-kinase, respectively. 
Of the fraction of tun that bound to microtubules, about 50% was 
phosphorylated at Ser-262 and Ser-356. These results suggest 
that Ser-262 and Ser-356 are very good substrates for CaM 
kinase II but their phosphorylations are not sufficient to achieve 
maximal inhibition of tau binding to microtubules. 
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I Introduction 
The paired helical filaments (PHF) found in Alzheimer dis- 
e, tse (AD) brain are composed primarily of the microtubule- 
a:~sociated protein tau [1]. PHF-tau is in a highly phosphoryl- 
a~ed state [2], and 21 phosphorylation sites have been identi- 
fi~'d. 10 of these sites are on Ser/Thr-Pro, the remaining 11 on 
non-Ser/Thr-Pro motifs [3-5]. These results suggest hat both 
woline-dependent protein kinases (PDPKs) and non-PDPKs 
a~'e involved in hyperphosphorylation of PHF-tau. 
Phosphorylation of tau modifies its function. PHF-tau 
bnds  to microtubules and promotes microtubule assembly 
o aly after it is dephosphorylated [6]. Inhibition of microtubule 
a~sembly is also observed after tau is phosphorylated by A 
k nase [7] and cdc2 kinase [8]. Phosphorylation of tau by a 
110 kDa kinase has been reported to strongly reduce the 
b nding of tau to microtubules [9]. 
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Abbreviations: PHF, paired helical filaments; A-kinase, cyclic AMP- 
dependent protein kinase; CaM kinase II, calcium/calmodulin- 
dependent protein kinase II; C-kinase, calcium/phospholipid-depen- 
d~mt protein kinase; CK-1, casein kinase-1 ; GSK-3, glycogen synthase 
kinase-3; MAP kinase, mitogen-activated protein kinase; PDPK, 
proline-dependent protein kinase 
The roles of Ser/Thr-Pro and non-Ser/Thr-Pro phosphoryl- 
ation in regulating tau function are still unclear. It was initi- 
ally reported that even after most of the Ser/Thr-Pro motifs 
on tau were phosphorylated by the PDPK, MAP kinase, the 
binding of tau was only moderately depressed [10]. Hence, the 
non-Ser/Thr-Pro phosphorylation sites in tau were implicated 
in regulating the binding of tau to microtubules The latter 
conclusion was further supported by a comparison of fetal 
tau and PHF-tau. Fetal tau [11], but not PHF-tau [6,11], 
can promote microtubule assembly. Fetal tau and PHF-tau 
are phosphorylated at 11 common sites. Of the additional 10 
sites found only in PHF-tau, seven are on non-Ser/Thr-Pro 
motifs [3,12]. One of these sites is Ser-262. It was reported 
that phosphorylation of this site is primarily responsible for 
decreasing the affinity of tau for microtubules [9,10]. 
In this study we have evaluated the abilities of four non- 
PDPKs (A-kinase, C-kinase, CK-1, CaM kinase II) and a 
PDPK (GSK-3) to phosphorylate Ser-262 and modify binding 
of tau to microtubules. Our results indicate that CaM kinase 
II and C-kinase are the most effective kinases in both of these 
categories. 
2. Materials and methods 
2.1. Materials 
The human tau clone 39 (kindly provided by M. Goedert) which 
encodes for tau isoform 3L, tau410 [13] was subeloned in E. coli and 
purified from cell extracts as described by us previously [14]. The 
purification of CK-1, GSK-3, CaM kinase II, C-kinase, and A-kinase 
has been described by us previously [14,15]. The monoclonal ntibody 
12E8 which recognizes tau phosphorylated at Ser-262 and/or Ser-356 
[16] was a generous gift from Dale Schenk of Athena Neurosciences 
(San Francisco, CA). The polyclonal tau antibody 92e was raised in 
rabbits as previously reported [17]. Tubulin was isolated from rat 
brain through two temperature-dependent cycles of microtubule poly- 
merization-depolymerization [18] followed by chromatography on 
phosphocellulose [19]. Taxol-stabilized microtubules were prepared 
by incubating tubulin (4 mg/ml) with taxol (20 ~M) in the presence 
of MES (0.1 M, pH 6.8), EGTA (1 raM), and PMSF (1 mM) at 37°C 
for 30 min. The microtubules were collected by centrifugation ver a 
cushion of 0.125 M sucrose at 50000Xg for 30 min at 32°C. 
2.2. Methods 
To generate the tau fragments, tau 2n. n, A.n. 1 and tau 267~41, total 
RNA and mRNA were isolated by RNA purification kit (Pharmacia- 
LKB Biotechnology) from the temporal lobe of a patient (6 h post- 
mortem) who was histologically confirmed to have AD. Tau fragment 
cDNAs were prepared from AD mRNA using specific primers by 
PCR and reagents and conditions as described in Gene Amp RNA 
PCR kit (Perkin Elmer Cetus). The amplification products were 
cloned into p Bluescript II KS + (Stratagene) and sequenced. Recom- 
binant plasmids (PRK 172) were transformed in E. eoli B121 cells, 
expressed, and purified as described previously [20]. Tau 3L or tau 
fragments 24 A, a.41 and 267-441 were phosphorylated at 30°C by the 
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different kinases in reaction mixtures normally containing 0.12 mg/ml 
tau or tau fragments, 5 mM MgC12, 10 mM 2-mercaptoethanol, 0.25 
mM ATP, and 40 mM HEPES (pH 6.8 or 7.5) as described by us 
previously [14,15]. Reactions were initiated by addition of kinases 
and, after suitable time of incubation, terminated by heating (95°C/ 
5 min). To assess the binding of tau to microtubules, 20 txg/ml tau 
(non-phosphorylated or phosphorylated bydifferent kinases) was in- 
cubated with 0.4 mg/ml taxol-stabilized microtubules for 30 min at 
37°C in buffer A (0.1 M HEPES (pH 6.8), 2 mM MgC12, 1 mM 
EDTA, 1 mM EGTA, 1 mM PMSF, 20 ~tM taxol, and 1 mM 
GTP). Tau bound to microtubules was separated from unbound tau 
by centrifugation at 50000×g for 30 min at 32°C. The pellet was 
washed once with buffer A. The combined supernatants and pellets 
were separately evaporated to dryness in a Speed Vac. All samples 
were run on either 10 or 12% (Fig. 3) SDS-polyacrylamide g ls, trans- 
ferred to nitrocellulose, and immunoblots probed by either 12E8 (1 
~tg/ml) or 92e (1/5000). Blots were then further probed with secondary 
antibodies which were either conjugated to alkaline phosphatase 
(Figs. 1-3) or labelled with 12~I (Fig. 4) [4]. The immunoreactive 
bands were visualized either by color development (Figs. 1 3) or by 
autoradiography (Fig. 4). Data were quantitated with the aid of either 
a Shimadzu CS-9000 Densitometer (Figs. 1-3) or a computerized Fuji 
1500 Video Imaging System (Fig. 4). 
3. Results 
3.1. Phosphorylation of Ser-262/Ser-356 by different kinases 
The monoclonal antibody 12E8 was previously shown to 
bind to tau which has been phosphorylated at Ser-262 and/or 
Ser-356 [16]. Using this antibody we have surveyed five 
kinases (A-kinase, C-kinase, CaM kinase II, CK-1, GSK-3) 
for their abilities to act as Ser-262 and/or Ser-356 kinases. In 
preliminary experiments, after phosphorylation of tau by the 
five kinases, acting either singly or in combination, binding of 
12E8 to tau was variously increased (data not shown). To 
evaluate which kinase is kinetically most likely to phosphor- 
ylate Ser-262 and/or Ser-356 in situ we have analyzed the time 
course of phosphorylation of these sites by the different ki- 
nases (Figs. 1 and 2). Blots with 12E8 are shown for x3L that 
was phosphorylated by A-kinase (Fig. 1A), C-kinase (Fig. 
1B), and CaM kinase II (Fig. 1C). Tau 3L that was not phos- 
phorylated bound only feebly to 12E8 (Fig. 1A, lane 1). To 
better appreciate the kinetics of phosphorylation of Ser-262 
and/or Ser-356 by the above three kinases (as well as CK-1 
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Fig. l. Increased 12E8 immunoreactivity of tau after its phosphoryl- 
ation by several kinases. Tau was incubated at 30°C in the presence 
of A-kinase (A) C-kinase (B), CaM kinase II (C), CK-1 (not 
shown), and GSK-3 (not shown). Samples were withdrawn at 0 min 
(lane 1), 10 min (lane 2), 30 min (lane 3), 90 min (lane 4), and 240 
min (lane 5) and immunoblotted with 12E8. 
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Fig. 2. Kinetics of phosphorylation f-Ser-262 and/or Ser-356 by 
the different kinases. Immunoblots for tau phosphorylated by CK-1 
(A), A-kinase (©), GSK-3 (O), C-kinase (D), and CaM kinase II 
(A) were quantified by densitometry. Binding of 12E8 to tau ob- 
served at 0 min (Fig. 1A, lane 1) was subtracted from all values. 
f f  D 
0 
and GSK-3) blots were scanned by densitometry and the data 
presented in Fig. 2. It can be seen that the rate of phosphor- 
ylation (in decreasing order) of these sites is CaM kinase 
II >> C-kinase >> GSK-3 --- A-kinase ~> CK-1. Further, CaM ki- 
nase II phosphorylated Ser-262 and/or Ser-356 to a 2-fold 
higher level (after 4 h) compared to the other kinases. It is 
obvious from these data that of the five kinases urveyed CaM 
kinase II is kinetically the best Ser-262 and/or Ser-356 kinase. 
3.2. CaM kinase H and C-kinase phosphorylates both Ser-262 
and Ser-356 
We have addressed the question of whether CaM kinase II 
phosphorylates Ser-262, Ser-356, or both. To do this we used 
two tau constructs: one containing both Ser-262 and Ser-356 
in the peptide Gln-244-Leu-441, the other containing only 
Ser-356 in the peptide Lys-267-Leu-441. These peptides 
were then used as substrates for CaM kinase II. The results 
with the Ser-356 peptide (Lys-267-Leu-441) are shown in Fig. 
3. When this peptide was incubated in the absence of CaM 
kinase II (lane 1) the subsequent binding of 12E8 was only 
minimal. After incubation in the presence of CaM kinase II 
(lane 2) the binding of 12E8 was enhanced 7-fold. In the 
presence of C-kinase a 2.5-fold increase was detected (not 
shown). The extent of phosphorylation f the peptide contain- 
ing both Ser-262 and Ser-356 (Gln-244-Leu-441) was 2-fold 
greater than that of the peptide containing only Ser-356 (Lys- 
267-Leu-441) (data not shown). These results suggest that 
CaM kinase II phosphorylates both Ser-262 and Ser-356 in 
Gln-244-Leu-441 and in full length (intact) tau. 
3.3. Binding of CaM kinase II-phosphorylated tau to 
microtubules 
We have evaluated what effect phosphorylation of Ser-262 
and Ser-356 may have on the ability of tau to bind to micro- 
tubules (Fig. 4). When tau was not phosphorylated we found 
that 94% of it bound to microtubules. Of the five kinases (A- 
kinase, C-kinase, CK-1, CaM kinase II, GSK-3) tried, C- 
kinase and CaM kinase showed the largest effect. After phos- 
phorylation of tau by these kinases the fraction of it that 
bound to microtubules was reduced to 52 and 59%, respec- 
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tively. Under the conditions of this experiment (1 h phosphor- 
ylation) A-kinase and CK-1 did not significantly affect bind- 
ing of tau to microtubules. With GSK-3 13% inhibition of 
binding was observed. We also found that with C-kinase- 
ar~d CaM kinase-phosphorylated au, 54 and 46%, respec- 
tively, of the total 12E8 immunoreactivity was found in tau 
that bound to microtubules. These results suggest hat the 
phosphorylation f Ser-262 and Ser-356 are not enough for 
a~,olishing the binding of tau to microtubules. 
4. Discussion 
In this study we have identified kinases that can phosphor- 
yl~te the non-Ser/Pro sites, Ser-262 and Ser-356, to various 
e~ tents. These kinases (in decreasing order of effectiveness) are 
C ~M kinase II >> C-kinase >> GSK-3 -= A-kinase ~> CK- 1. Phos- 
pilorylation of Ser-262 and/or Ser-356 by CK-1 was very slow 
a~td became significant only after many hours of incubation at 
3~ ,°C. CaM kinase II phosphorylated Ser-262 rapidly and to a 
g, eater than 2-fold higher extent compared to the other ki- 
n,~ses. This is the first study to identify CaM kinase II and C- 
k~nase as Ser-262 and Ser-356 kinases. Ser-262 and Ser-356 
~re previously shown to be phosphorylated by A-kinase [9] 
arid GSK-30t [21], and Ser-262 by GSK-3[3 [22]. Unlike our 
results (Fig. 2), Ser-262 was phosphorylated by GSK-3a and 
GSK-3~ only in the presence [21,22], and not in the absence 
[~ 3], of heparin. One possible reason why we found phosphor- 
yiation of Ser-262 and Ser-356 in the absence of heparin is 
t lat we have used a single human tau isoform (z3L) in our 
sl ady compared to the use of bovine tau (a mixture of six tau 
is,)forms) in the previous studies [21-23]. We have recently 
stown that tau isoforms are phosphorylated at different rates 
artd to different extents by various kinases, including GSK-3 
[: ~]. 
Our data support the conclusion that phosphorylation f
S~:r-262 and Ser-356 is not enough to prevent he binding of 
t,'u to microtubules. In recent studies [9] it was shown that 
p!tosphorylation f Ser-262 by a 110 kDa kinase was primar- 
i l '  responsible for reducing the affinity of tau for binding to 
rr~icrotubules. Our results do not support this conclusion. 
Although Ser-262 and Ser-356 are maximally phosphorylated 
b ' CaM kinase II, 59% of the tau remain bound to micro- 
n~bules. This result suggests that the phosphorylation f Ser- 
2~,2 and Ser-356 is not enough for eliminating the interaction 
o tau with microtubules. The phosphorylation f other sites 
is obviously required. A similar conclusion to ours was also 
i i~i~%~ ~i~i  ¸ ~ ~ii~iill 
18.4 __~,~ 
1 2 
Fig. 3. CaM kinase II phosphorylates Ser-356 in addition to Ser- 
262. The tau construct Lys-267-Leu-441 lacking Ser-262 but con- 
tanning Ser-356 was incubated for 1 h at 30°C in either the absence 
(lane 1) or presence (lane 2) of CaM kinase II. Samples were then 
immunoblotted with 12E8. The positions of marker proteins (in 
kDa) are shown on the left. 
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Fig. 4. Effect of phosphorylation f tau by different kinases on its 
ability to bind to microtubules. Tau was separately incubated for 1 h 
at 30°C in either the absence (none) or presence of A-kinase, C-ki- 
nase, CK-1, CaM kinase II, and GSK-Y In parallel incubations 32P i 
incorporation i to tau by these kinases after 1 h was determined to
be 0.90, 0.95, 3.10, 1.40, and 0.98 mol/mol tau, respectively. The re- 
actions were stopped by heating at 95°C for 5 min. Binding of the 
different species of heat-stable phosphorylated tau to taxol-stabilized 
microtubules was then quantified by using the polyclonal phosphor- 
ylation-independent tau antibody 92e. Data (mean + SD) were from 
three separate experiments. 
reached using phosphorylated tau from human biopsy-brain 
samples [16]. 
The identities of the additional sites (besides Ser-262 and 
Ser-356) whose phosphorylation may be required to com- 
pletely abolish binding of tau to microtubules are presently 
unclear. It is surprising that no inhibition of binding was 
detected with CK-l-phosphorylated tau. Of several non- 
PDPKs we have compared in our studies, CK-1 is among 
the best tau kinases. Under the conditions used for this study 
x3L was phosphorylated by CK-1 to the extent of ,~ 3 mol Pi/ 
mol tau (see legend to Fig. 4 and [14,24]). Although we have 
not yet identified the sites phosphorylated by CK-1 it is pos- 
sible that this kinase does not effectively phosphorylate sites in 
the microtubule-binding domains of tau. Ser-262 and Ser-356 
are both located in these domains and are rapidly phosphory- 
lated by C-kinase and CaM kinase II thereby causing inhibi- 
tion of binding of tau to microtubules. In addition, C-kinase 
has been reported to also phosphorylate Set-305 [9] and Ser- 
324 [25], both also located in the microtubule binding do- 
mains. Similarly, A-kinase has been reported to phosphorylate 
several sites in tau microtubule-binding domains: Ser-262, 
Ser-293, Set-305, Ser-324, Ser-356 [7,9]. Yet we did not ob- 
serve any significant inhibition of tau binding to microtubules 
by A-kinase. As we observed for Ser-262 and Ser-356 (Fig. 2) 
it is possible that the rates of phosphorylation f these sites by 
A-kinase are slow and they are incompletely phosphorylated 
after 1 h (Fig. 4). Although Ser-262 and Ser-356 are phos- 
phorylated by GSK-3 at 75% the level achieved with C-kinase 
(after 1 h) the binding of tau to microtubules was reduced by 
only 13% compared to a 42% reduction with C-kinase (Fig. 
4). These results further einforce the idea that additional sites 
need to be phosphorylated for effective inhibition of tau bind- 
ing to microtubules. It is not known whether GSK-3 can 
phosphorylate other sites (besides Ser-262 and Ser-356) in 
the microtubule binding domains in the absence of heparin. 
In the presence of heparin Ser-324, is also phosphorylated 
[21,22]. 
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It is possible that phosphorylation of both Ser/Thr-Pro and 
non-Ser/Thr-Pro sites on tau may be required for a maximal 
effect on microtubule function to be observed. This seems to 
be true for PHF-tau. PHF-tau in its fully phosphorylated 
state (10 Ser/Thr-Pro sites, 11 non-Ser/Thr-Pro sites) fails to 
promote microtubule assembly, but does so after dephosphor- 
ylation [6,11]. We have recently shown that after an initial 
prephosphorylation of tau by non-PDPKs (A-kinase, C- 
kinase, CaM kinase II) several sites on tau that were pre- 
viously inaccessible became readily accessible to a PDPK 
such as GSK-3 [14,24]. Hence potent regulation of tau func- 
tion may require the concerted actions of both PDPK and 
non-PDPKs. 
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